Oncolytics: Reolysin purges cancer cells from stem cell transplants following chemotherapy

By E. Janene Geiss

Philadelphia, Feb. 21 - Oncolytics Biotech Inc. said Tuesday that medical studies show that a common virus may be able to eliminate cancer cells from autologous stem cell transplants.

Researchers at Oncolytics have patented a way to use the reovirus to purge cancer cells from autologous stem cell transplants that are reintroduced to the body following high-dose chemotherapy, according to a company news release.

Autologous transplantation following high-dose chemotherapy is a proven treatment alternative for many types of cancer and is extensively used by doctors for both solid tumors and tumors of the blood.

In fact, autologous blood and bone marrow transplant procedures surpass the number of transplants derived from donors, officials said.

During the procedure, blood stem cells are extracted from a patient prior to high-dose chemotherapy. Once the chemotherapy is completed, the patient's own blood stem cells are transplanted back into the patient.

The primary advantage of autologous transplants is that there is no risk of rejection, officials said.

However, it has been estimated that as many as 30% of these autologous stem cell transplants are contaminated by cancer cells and there is a risk that they may contribute to clinical relapse of the cancer by reintroducing cancer cells back into the body, officials said.

"If we can use our reovirus-based therapy, Reolysin, to purge the blood products of cancer cells before they are reintroduced to the body, it could represent an important step forward in increasing the success of these transplants," Matt Coffey, chief scientific officer of Oncolytics, said in the release.

When introduced to the blood, the reovirus enters cancer cells, replicates within them and ultimately kills them.

It works by replicating within cancer cells that have an activated Ras pathway, a common mutation that is shared by about two-thirds of all human cancers.

The results of a study to purge cancer cells from autologous stem cell preparations using the reovirus were previously published in a March 2003 issue of Blood. Researchers concluded in the article that the use of reovirus may be an effective way to purge cancer cells in blood used for ex-vivo autologous stem cell transplants.

The link to reovirus' cancer-killing ability was established after it was discovered that it reproduces well in various cancer cell lines including those found in blood cancers, officials said.

"Having an effective method to purge cancer cells from autologous blood stem cell transplants may offer doctors another important tool in fighting cancer," Coffey said in the release. "Patenting this innovation provides us with an important extension of the potential use of the reovirus for the treatment of cancer."

Oncolytics is a Calgary, Alta., pharmaceutical company that focuses on development of products to treat a wide variety of human cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.